View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 29, 2019updated 19 Sep 2022 12:40pm

Theranica’s wearable device for migraine relief gets FDA approval

Israel-based Theranica Bioelectronics has received de novo approval from the US Food and Drug Administration (FDA) for a smartphone-controlled wearable device to help treat acute migraines.

Israel-based Theranica Bioelectronics has received de novo approval from the US Food and Drug Administration (FDA) for a smartphone-controlled wearable device to help treat acute migraines.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Named Nerivio Migra, the electroceutical uses remote electrical neuromodulation and can be attached to the patient’s upper arm for a personalised pain relief programme.

The wearable device comprises electrodes, a battery and Theranica’s smart chip, which generates electrical pulses to stimulate the sensory nerves under the skin and create conditioned pain modulation (CPM).

Designed for the acute treatment of adult patients who do not have chronic migraines, Nerivio Migra can be controlled using an intuitive smartphone application.

Theranica CEO and co-founder Alon Ironi said: “While the company is preparing to launch the Nerivio Migra in the US market later this year at an affordable price, we remain committed to continuing our clinical development, expanding the use of remote electrical neuromodulation therapy for additional indications.”

The FDA decision is based on data obtained from a prospective, randomised, double-blind, placebo-controlled, multi-centre pivotal study that involved 252 patients at 12 clinics.

According to the company, data showed a 66.7% pain relief response within two hours.

Study principal investigator Dr Brian Grosberg said: “The results of the study demonstrate a high efficacy ratio for single as well as multiple attacks, both at two and 48 hours after treatment.”

“The company is preparing to launch the Nerivio Migra in the US market later this year at an affordable price.”

Migraine attacks are the third most common disease and are known to affect 14.7% of the global population. In the US alone, the condition costs $17bn annually.

Founded in 2016, Theranica is focused on developing wireless neuromodulation technologies.

The company has identified seven different painful disorders that could be potentially addressed with non-invasive, drug-free electroceuticals.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network